2023
DOI: 10.1016/j.apsb.2022.10.002
|View full text |Cite
|
Sign up to set email alerts
|

Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
17
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 37 publications
(18 citation statements)
references
References 196 publications
(275 reference statements)
0
17
0
Order By: Relevance
“…Furthermore, the relationship between methylation and gene expression varies from gene to gene. We found that DNA methylation of the ATP2A2 gene, which is associated with tumor multi‐drug resistance, [ 19 ] negatively regulated gene expression (Figure 3E), whereas gene expression of the SLK gene, which is the target of the leukemia therapeutic drug dasatinib, [ 20 ] was positively correlated with DNA methylation levels (Figure 3F). These findings collectively indicate significant involvement of DNA methylation in gene expression regulation, although it is not the sole determinant.…”
Section: Resultsmentioning
confidence: 99%
“…Furthermore, the relationship between methylation and gene expression varies from gene to gene. We found that DNA methylation of the ATP2A2 gene, which is associated with tumor multi‐drug resistance, [ 19 ] negatively regulated gene expression (Figure 3E), whereas gene expression of the SLK gene, which is the target of the leukemia therapeutic drug dasatinib, [ 20 ] was positively correlated with DNA methylation levels (Figure 3F). These findings collectively indicate significant involvement of DNA methylation in gene expression regulation, although it is not the sole determinant.…”
Section: Resultsmentioning
confidence: 99%
“…At the transporter level, the levels of BCRP and ABCC10 (i.e., multidrug resistance-associated protein 7, MRP7) in target cells were directly associated with FTO levels in EVs. Changes in m 6 A levels in the ABCC10 gene were also demonstrated experimentally; m 6 A levels in the ABCG2 gene (codifying BCRP) were not investigated [168]. Altogether, FTO-carrying EVs released from drug-resistant cells appear to result in FTO upregulation in drug-sensitive cells.…”
Section: Regulatory Proteinsmentioning
confidence: 92%
“…In line with this, FTO was overexpressed in serum EVs from gefitinib-resistant lung cancer patients compared to serum EVs from gefitinib-sensitive patients. Also, treatment of PC9 gefitinib-sensitive cells with PC9/GR and H1975 EVs increased resistance to the drug, concomitant with a decrease in m 6 A content in target cells. Since the effect was prevented by FTO knockdown in donor cells, a major role of FTO carried by EVs can be proposed.…”
Section: Regulatory Proteinsmentioning
confidence: 98%
“…Chemotherapy is the main means of cancer clinical treatment, and the emergence of multidrug resistance (MDR) is the bottleneck problem that may lead to chemotherapy failure and tumor recurrence [1,2]. The aberrant redox homeostasis with both reactive oxide species (ROS) production and antioxidant modulators (e.g.…”
Section: Introductionmentioning
confidence: 99%